{"nct_id":"NCT03535740","title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","status":"COMPLETED","status_verified_date":"2025-07","start_date":"2019-01-31","start_date_type":"ACTUAL","primary_completion_date":"2020-09-30","primary_completion_date_type":"ACTUAL","completion_date":"2024-08-21","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["TAK"]}